-
Mashup Score: 0PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT - 1 year(s) ago
The last decade has witnessed a remarkable reduction in graft-versus-host disease (GVHD) rates, secondary to introducing new methods for GVHD prevention [1]. The use of post-transplantation cyclophosphamide (PTCY) to mitigate bidirectional alloreactivity has been a milestone in haploidentical hematopoietic stem cell transplantation (haploHSCT) [2–4]. Consequently with its efficacy, the use of…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
#ASTCTChat Q1: Does your standard GVHD prophylaxis vary according to age? https://t.co/54NwplWgNL https://t.co/xVauA9WRZC